Process for preparing anti-obesity protein |
| OF THE INVENTION For purposes of the present invention, as disclosed and claimed herein, the ... |
|
Use of GLP-1 or analogs to abolish catabolic changes after surgery |
| The present invention therefore presents for the first time a method of attenuating post-surgical ... |
|
Leptospira rare outer membrane proteins |
| The present invention presents two novel leptospiral membrane proteins: LipL1 and LipL2. In ... |
|
Interleukin-1 beta converting enzyme like apoptotic protease-6 |
| Toward these ends, and others, it is an object of the present invention to provide polypeptides, ... |
|
Expressed sequence tags and encoded human proteins |
| The present invention relates to purified, isolated, or enriched 5' ESTs which include sequences ... |
|
C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof |
| The invention claimed is: 1. An isolated PC-LECTIN protein comprising the amino acid sequence of SEQ... |
|
Antibodies for use in determining hemoglobin A.sub.1c |
| It is accordingly an object of the present invention to provide a comparatively simple, inexpensive,... |
|
Haptens, tracers, immunogens and antibodies for immunoassays for cotinine derivatives |
| OF THE INVENTION A hapten of the invention is substantially optically pure, and is particularly ... |
|
|
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
| Details |
Inventors: Ledbetter, Jeffrey A.; Gilliland, Lisa K.; Hayden, Martha S.; Linsley, Peter S.; Bajorath, Jurgen; Fell, H. Perry;
Assignee: Bristol-Myers Squibb Company (New York, NY)
Primary Examiner: Guzo; David
Assistant Examiner:
Attorney, Agent or Firm: Merchant, Gould, Smith, Edell Welter & Schmidt
The present invention provides an expression vector encoding monospecific or bispecific fusion protein. In one embodiment the expression vector encodes a monospecific fusion protein, which vector comprises a recombinant monospecific single chain cassette comprising a DNA sequence encoding a first binding domain capable of binding a cell surface antigen. |
|
DETAILED DESCRIPTION OF THE INVENTION DEFINITIONS As used in this application, the following words or phrases have the meanings specified. As used herein, a "bispecific fusion protein" means any immunologically reactive molecule which specifically recognizes and binds at least two different targets at alternate times or at the same time and is expressed as a single chain. As used herein, a "monospecific fusion protein" means any immunologically reactive molecule which specifically recognizes and binds a target and is a complex comprising two heavy immunoglobulin chains, two light immunoglobulin chains, or a heavy and/or light immunoglobulin chain and/or any portions thereof and is expressed as a single chain. As used herein, an "expression vector" means a nucleic acid molecule comprising (1) a promoter and other sequences (e. g. leader sequences) necessary to direct expression of a desired gene or DNA sequence and (2) the desired gene or DNA sequence. Optionally, the nucleic acid molecule may comprise a poly A signal sequence to enhance the stability of the gene transcript and/or an enhancer sequence to increase the transcription of the gene thereby affecting the expression of the gene. As used herein, a "binding domain" means a binding site which recognizes and binds the entire binding area of a target or any portion thereof. Examples include, but are not limited to, (1) a single variable region of an antibody (V. sub. L or V. sub. H); (2) two or more variable regions (e. g. V. sub. L +V. sub. H ; V. sub. L +V. sub. L ; or V. sub. H +V. sub. H) or the complementary determining region (CDR) thereof, or (3) an antigen (such as a leucocyte antigen) or a portion thereof. As used herein, a "molecular tag" includes any DNA sequence encoding a molecule which may facilitate detection and purification of the fusion proteins described herein. As used herein, a "bispecific single chain cassette" includes a DNA sequence encoding a first binding domain capable of binding a target and a DNA sequence encoding a second binding domain capable of binding a target, each domain capable of binding a different target at alternate times or at the same time, both domains encoded by DNA sequences being on the same cassette
|
| Related patents |
|
|
MYPPPY variants of CTL A4 and uses thereof
OF THE INVENTION Definition As used in this application, the following words or phrases have the meanings specified. As used herein "blocking B7 interaction" means to ...
|
|
|
CTLA4 receptor and uses thereof
OF THE INVENTION DEFINITION As used in this application, the following words or phrases have the meanings specified. As used herein "blocking B7 interaction" means to ...
|
|
|
CTLA4/CD28Ig hybrid fusion proteins and uses thereof
OF THE INVENTION DEFINITION As used in this application, the following words or phrases have the meanings specified. As used herein "blocking B7 interaction" means to ...
|
|
|
Method of regulating cellular processes mediated by B7 and CD28
Accordingly, the present invention identifies the B7 antigen as a ligand recognized by the CD28 receptor. The B7 antigen, or its fragments or derivatives are reacted ...
|
|
|
Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
This invention is based, at least in part, on the discovery of novel ligands which bind a T cell surface molecule and induce antigen specific apoptosis in an activated T ...
|
|
|
Method for generating and identifying antibodies directed against a B7
Accordingly, the present invention identifies the B7 antigen as a ligand recognized by the CD28 receptor. The B7 antigen, or its fragments or derivatives are reacted ...
|
|
|
Polypeptide that interacts with heat shock proteins
Described herein are the isolation and characterization of a polypeptide, particularly a tetratricopeptide repeat (TPR)-containing polypeptide that is an interactive ...
|
|
|
1,2-Biguanides
What is claimed is: 1. A substituted biguanide of the formula ##EQU8## wherein R.sub.1 is alkyl of 1-8 carbon atoms, R'.sub.1 is hydrogen or alkyl of 1-8 carbon atoms ...
|
|
|
Biguanide salts
OF THE INVENTION The invention relates to biguanide salts. In another aspect, the invention relates to pharmaceutical preparations which contain the aforementioned ...
|
|
|
Inhibitors of dipeptidyl-aminopeptidase type IV
What is claimed is: 1. A method for treating transplant rejection in a patient comprising administering to said patient an inhibitor of DP-IV, having the structure: ##STR...
|
|
|